Vifor builds in kidney disease with Sanifit, Inositec buysOn the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by Share XVifor builds in kidney disease with Sanifit, Inositec buyshttps://pharmaphorum.com/news/vifor-builds-in-kidney-disease-with-sanifit-inositec-buys/
Novartis’ iptacopan hits the mark in rare kidney disease C3GNovartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying Share XNovartis’ iptacopan hits the mark in rare kidney disease C3Ghttps://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/
Vifor, Angion organ damage drug fails phase 3 kidney transplant studyVifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this Share XVifor, Angion organ damage drug fails phase 3 kidney transplant studyhttps://pharmaphorum.com/news/vifor-angion-organ-damage-drug-fails-phase-3-kidney-transplant-study/
FDA rejects FibroGen/AZ’s roxadustat, asking for new trialThe FDA has demanded another clinical trial of FibroGen and AstraZeneca’s roxadustat for anaemia caused by chronic kidney Share XFDA rejects FibroGen/AZ’s roxadustat, asking for new trialhttps://pharmaphorum.com/news/fda-rejects-fibrogen-azs-roxadustat-asking-for-new-trial/
FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiaSafety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for Share XFDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemiahttps://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/
Sanofi’s venglustat bombs again, but isn’t dead yetShortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal Share XSanofi’s venglustat bombs again, but isn’t dead yethttps://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAAstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to Share XAstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAhttps://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/
FDA sets September review date for Calliditas’ rare kidney disease drugCalliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA Share XFDA sets September review date for Calliditas’ rare kidney disease drughttps://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/
